


HPW

<b>TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT</b> (Under 37 CFR 1.97(b) or 1.97(c))				<b>Docket No.</b> Army156A	
In Re Application Of: Eckels et al					
Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/626,315	July 24, 2003	not known	000041022	1653	
Title: Live-Attenuated Multivalent Dengue Vaccine					
(DIVISIONAL APPLICATION OF SERIAL NO. 09/535,117)					
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450					
37 CFR 1.97(b)					
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.					
37 CFR 1.97(c)					
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:					
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);					
OR					
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).					

**TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT**  
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.  
Army156A

In Re Application: Eckels et al.



Application No. 10/626,315	Filing Date July 24, 2003	Examiner not known	Customer No. 000041022	Group Art Unit 1653	Confirmation No.
-------------------------------	------------------------------	-----------------------	---------------------------	------------------------	------------------

Title: Live-Attenuated Multivalent Dengue Vaccine

(DIVISIONAL APPLICATION OF SERIAL NO. 09/535,117)

**Payment of Fee**

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of \_\_\_\_\_ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. 21-0380 as described below.
- ☐ Charge the amount of \_\_\_\_\_
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

**WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.**

**Certificate of Transmission by Facsimile\***

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. \_\_\_\_\_)

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature

\_\_\_\_\_  
Typed or Printed Name of Person Signing Certificate

**\*This certificate may only be used if paying by deposit account.**

\_\_\_\_\_  
Signature

**Certificate of Mailing by First Class Mail**

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" Sept. 14, 2004

\_\_\_\_\_  
(Date)

\_\_\_\_\_  
Signature of Person Mailing Correspondence

Marlana Titus

\_\_\_\_\_  
Typed or Printed Name of Person Mailing Certificate


Dated: September 14, 2004

Marlana Titus, Reg. No. 35,843  
for Elizabeth Arwine, Reg. No. 45,867  
Attorney for applicant  
U.S. Army Medical Research and Materiel Command  
504 Scott Street  
Ft. Detrick, MD 21702-5012  
(301) 977-7227

CC:

# INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

Army156A

Application Number

10/626,315

Applicant(s)

Eckels et al.

Filing Date

July 24, 2003

Group Art Unit

1653

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A	5,723,130	3/3/98	Hancock et al.	424	211.1	9/16/96

## U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

## FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

## OTHER DOCUMENTS

(Including Author, Title, Date, Pertinent Pages, Etc.)

	B	Eckels et al., "Selection of Attenuated Dengue-4 Viruses by Serial Passage in Primary Kidney Cells", Am. J. Trop. Med. Hyg., 33(4), 1984, pages 684-689.
	C	Liu et al., "Study of Attenuation of Dengue Type-4 Virus by Consecutive Passages in Primary Hamster Kidney Tissue Culture", Virologica Sinica, 1989, pages 38-44.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**INFORMATION DISCLOSURE CITATION***(Use several sheets if necessary)*

Docket Number (Optional)

**Army156A**

Application Number

**10/626,315**

Applicant(s)

**Eckels et al.**

Filing Date

**July 24, 2003**

Group Art Unit

**1653**\*EXAMINER  
INITIAL**OTHER DOCUMENTS** *(Including Author, Title, Date, Pertinent Pages, Etc.)*

D

**Smith and Wright, "Synthesis of Proteins and Glycoproteins in Dengue Type 2 Virus-infected Vero and Aedes albopictus Cells", J. Gen. Viro. (1985), 66, pages 559-571.**

E

**Kraiselburd, Edmundo, "Comparative Infectivity Determination of Candidate Live Dengue Virus Vaccine in Monkeys, Mosquitoes and cell cultures", July 27, 1987, Puerto Rico Univ., San Juan, pages 1-21**

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.